| abstract |
Use of an ERRy agonist or a pharmaceutically acceptable salt thereof, for the prevention, delay of progress, or treatment of diabetes, insulin resistance, metabolic disease Metabolic syndrome, dyslipidemia, obesity, overweight, neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, Huntington's disease, or improved resistance to exercise. |